as 05-20-2024 10:33am EST
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Founded: | 1949 | Country: | Italy |
Employees: | N/A | City: | N/A |
Market Cap: | 5.7B | IPO Year: | 2021 |
Target Price: | $34.29 | AVG Volume (30 days): | 538.4K |
Analyst Decision: | Buy | Number of Analysts: | 7 |
Dividend Yield: | 0.28% | Dividend Payout Frequency: | Annual |
EPS: | 0.55 | EPS Growth: | -7.27 |
52 Week Low/High: | $20.01 - $36.30 | Next Earning Date: | 05-09-2024 |
Revenue: | $1,177,560,870 | Revenue Growth: | 7.31% |
Revenue Growth (this year): | 11.48% | Revenue Growth (next year): | 12.15% |
STVN Breaking Stock News: Dive into STVN Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
Insider Monkey
8 days ago
Simply Wall St.
8 days ago
Simply Wall St.
10 days ago
Thomson Reuters StreetEvents
10 days ago
MT Newswires
11 days ago
MT Newswires
11 days ago
MT Newswires
11 days ago